Terapi Farmakologi Meningitis Tuberkulosis

Authors

  • Adira Rahmawaty Universitas Padjadjaran

DOI:

https://doi.org/10.46799/jhs.v4i5.892

Keywords:

Meningitis TB, Pharmacology, Therapy

Abstract

Tuberculosis Meningitis is a type of extrapulmonary TB that is very deadly because it infects the central nervous system. Therefore post-diagnosis pharmacological therapy is needed to maintain and improve the quality of life of patients. Based on this, there were 210 articles related to keywords and 15 articles that met the inclusion criteria. The main pharmacological therapies for patients with tuberculous meningitis include rifampicin, isoniazid, pyrazinamide, ethambutol, dexamethasone, and third-class cephalosporin antibiotics.

References

Buchari. (2019). Uji Serologi pada Penderita Tuberkulosis Aktif. Jurnal Kedokteran Nanggroe Medika, 2(4), 18–26.

Charlie, L., Abay, S., Tesfaye, A., Mlera, R., Mwango, S., & Goretti, M. (2021). Safety and efficacy of high-dose rifampicin in the management of tuberculosis meningitis: Systematic review and meta-analysis. International Journal of Mycobacteriology, 10(3), 312–319. https://doi.org/10.4103/IJMY.IJMY_135_21

Cresswell, F. V., Meya, D. B., Kagimu, E., Grint, D., Te Brake, L., Kasibante, J., Martyn, E., Rutakingirwa, M., Quinn, C. M., Okirwoth, M., Tugume, L., Ssembambulidde, K., Musubire, A. K., Bangdiwala, A. S., Buzibye, A., Muzoora, C., Svensson, E. M., Aarnoutse, R., Boulware, D. R., & Elliott, A. M. (2021). High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clinical Infectious Diseases, 73(5), 876–884. https://doi.org/10.1093/CID/CIAB162

Davis, A. G., Rohlwink, U. K., Proust, A., Figaji, A. A., & Wilkinson, R. J. (2019). The pathogenesis of tuberculous meningitis. Journal of Leukocyte Biology, 105(2), 267–280. https://doi.org/10.1002/JLB.MR0318-102R

Davis, A., Meintjes, G., & Wilkinson, R. J. (2018). Treatment of Tuberculous Meningitis and Its Complications in Adults. Current Treatment Options in Neurology, 20(3). https://doi.org/10.1007/S11940-018-0490-9

Donovan, J., Thwaites, G. E., & Huynh, J. (2020). Tuberculous meningitis: where to from here? Current Opinion in Infectious Diseases, 33(3), 259–266. https://doi.org/10.1097/QCO.0000000000000648

Gopalaswamy, R., Shanmugam, S., Mondal, R., & Subbian, S. (2020). Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment. Journal of Biomedical Science, 27(1). https://doi.org/10.1186/S12929-020-00667-6

Huang, M., Ma, Y., Ji, X., Jiang, H., Liu, F., Chu, N., & Li, Q. (2023). A study of risk factors for tuberculous meningitis among patients with tuberculosis in China: An analysis of data between 2012 and 2019. Frontiers in Public Health, 10. https://doi.org/10.3389/FPUBH.2022.1040071

Manyelo, C. M., Solomons, R. S., Walzl, G., & Chegou, N. N. (2021). Tuberculous Meningitis: Pathogenesis, Immune Responses, Diagnostic Challenges, and the Potential of Biomarker-Based Approaches. Journal of Clinical Microbiology, 59(3). https://doi.org/10.1128/JCM.01771-20

Misra, U. K., Kalita, J., Sagar, B., & Bhoi, S. K. (2018). Does adjunctive corticosteroid and aspirin therapy improve the outcome of tuberculous meningitis? Neurology India, 66(6), 1672–1677. https://doi.org/10.4103/0028-3886.246278

Paliwal, V. K., Das, A., Anand, S., & Mishra, P. (2019). Intravenous Steroid Days and Predictors of Early Oral Steroid Administration in Tuberculous Meningitis: A Retrospective Study. The American Journal of Tropical Medicine and Hygiene, 101(5), 1083–1086. https://doi.org/10.4269/AJTMH.19-0416

PDPI. (2021). PEDOMAN DIAGNOSIS DAN PENATALAKSANAAN TB DI INDONESIA.

Quinn, C. M., Poplin, V., Kasibante, J., Yuquimpo, K., Gakuru, J., Cresswell, F. V., & Bahr, N. C. (2020). Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum of Disease. Life (Basel, Switzerland), 10(11), 1–26. https://doi.org/10.3390/LIFE10110262

Riaz, M., Akram, M., Egbuna, C., Ifemeje, J. C., Chikwendu, J. C., Patrick-Iwuanyanwu, K. C., Olatunde, A., Tijjani, H., Adetunji, C. O., Shivamallu, C., Olisah, M. C., & Uche, C. Z. (2022). Dexamethasone. Coronavirus Drug Discovery: Volume 1: SARS-CoV-2 (COVID-19) Prevention, Diagnosis, and Treatment, 169–179. https://doi.org/10.1016/B978-0-323-85156-5.00028-6

Ruiz-Bedoya, C. A., Mota, F., Tucker, E. W., Mahmud, F. J., Reyes-Mantilla, M. I., Erice, C., Bahr, M., Flavahan, K., de Jesus, P., Kim, J., Foss, C. A., Peloquin, C. A., Hammoud, D. A., Ordonez, A. A., Pardo, C. A., & Jain, S. K. (2022). High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis. The Journal of Clinical Investigation, 132(6). https://doi.org/10.1172/JCI155851

Srivastava, S., Van Zyl, J., Cirrincione, K., Martin, K., Thomas, T., Deshpande, D., Alffenaar, J. W., Seddon, J. A., & Gumbo, T. (2020). Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children. The Pediatric Infectious Disease Journal, 39(12), 1092. https://doi.org/10.1097/INF.0000000000002857

Sy, M. C. C., Espiritu, A. I., & Pascual, J. L. R. (2022). Global Frequency and Clinical Features of Stroke in Patients With Tuberculous Meningitis: A Systematic Review. JAMA Network Open, 5(9), E2229282. https://doi.org/10.1001/JAMANETWORKOPEN.2022.29282

Wang, W., Gao, J., Liu, J., Qi, J., & Zhang, Q. (2022). Clinical Efficacy of Dexamethasone in the Treatment of Patients with Tuberculous Meningitis: A Meta-Analysis. Contrast Media & Molecular Imaging, 2022. https://doi.org/10.1155/2022/2180374

Downloads

Published

2023-05-25

Issue

Vol. 4 No. 5 (2023): Journal Health Sains

Section

Articles

License

Copyright (c) 2023 Adira Rahmawaty

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under aCreative Commons Attribution-ShareAlike 4.0 International (CC-BY-SA). that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.